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Abstract
Background: The worldwide emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant
tuberculosis (XDR-TB) has posed additional challenges for global tuberculosis (TB) control efforts, as limited treatment
options are available and treatment outcomes are often sub-optimal. This study determined treatment outcomes
among a cohort of MDR-TB and XDR-TB patients in Hunan Province, China, and identified factors associated with poor
treatment outcomes.
Methods: We conducted a retrospective study using data obtained from medical records of TB patients in Hunan
Chest Hospital, and from the internet-based TB management information system managed by the Tuberculosis Control
Institute of Hunan Province, for the period 2011 to 2014. Treatment outcomes were assessed for patients diagnosed with
MDR-TB (TB resistant to at least isoniazid and rifampicin) and XDR-TB (MDR-TB plus resistance to any fluoroquinolone
and at least 1 second-line injectable drug). Cumulative incidence functions were used to estimate time to events (i.e.
poor treatment outcomes, loss to follow-up, and unfavourable treatment outcomes); and a competing-risks survival
regression model was used to identify predictors of treatment outcomes.
Result: Of 481 bacteriologically-confirmed patients, with a mean age of 40 years (standard deviation SD ± 13 years), 10
(2%) had XDR-TB and the remainder (471; 98%) had MDR-TB. For the entire cohort, treatment success was 57% (n = 275);
58% (n = 272) for MDR-TB and 30% (n = 3) for XDR-TB. Overall, 27% were lost to follow-up (n = 130), 27% (n = 126) for
MDR-TB and 40% (n = 4) for XDR-TB; and 16% had a poor treatment outcome (n = 76), 15% for MDR-TB and 30% (n = 3)
for XDR-TB. Of the 10 XDR-TB patients, 3 (30%) completed treatment, 3 (30%) died and 4 (40%) were lost to follow-up. Of
the 471 MDR-TB patients, 258 (57%) were cured, 16 (3%) completed treatment, 13 (3%) died, 60 (13%) experienced
treatment failure, and 126 (27%) were lost to follow-up. Resistance to ofloxacin was an independent predictor of poor
(AHR = 3.1; 95%CI = 1.5, 6.3), and unfavourable (AHR = 1.7; 95%CI = 1.07, 2.9) treatment outcomes. Patients who started
treatment during 2011–2012 (AHR = 2.8; 95% CI = 1.5, 5.3) and 2013 (AHR = 2.1; 95% CI = 1.2, 3.9) had poorer treatment
outcomes compared to patients who started treatment during 2014.
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Conclusion: Patients with MDR-TB and XDR-TB had low rates of treatment success in Hunan Province, especially among
patients who started treatment during 2011 to 2013, with evidence of improved treatment outcomes in 2014. Resistance
to ofloxacin was an independent predictor of poor treatment outcomes.
Keywords: Multidrug-resistant, Extensively drug resistant, Tuberculosis, Treatment outcomes, China
Background
Tuberculosis (TB) remains the largest infectious disease
killers worldwide [1]. According to the World Health
Organization (WHO), in 2015, there were an estimated
10.4 million new TB cases, 1.4 million TB deaths and
another 0.4 million deaths among people with TB and
HIV [2]. Multidrug-resistant tuberculosis (MDR-TB), de-
fined as TB resistant to at least isoniazid and rifampicin,
and extensively drug-resistant tuberculosis (XDR-TB),
defined as MDR-TB plus resistance to any fluoro-
quinolone and at least 1 second-line injectable drug,
have become major public health problems, and pose
additional challenges for global TB control efforts [3,
4]. In 2015, there were an estimated 480,000 new
cases of MDR-TB and an additional 100, 000 new
cases of rifampicin resistant (RR) TB [2]. In the same
year, there were 7579 new cases of XDR-TB reported
from 74 countries [2]. Approximately 45% of the
global MDR-TB burden occurs in China, India and
the Russian Federation [2].
China is one of the top 30 MDR-TB and TB burden
countries in the world [5]. According to WHO’s latest
global TB report, there were an estimated 57,000 cases
of MDR/RR-TB among notified pulmonary TB cases in
China in 2015 [2]. This accounted for 12% of the total
MDR-TB burden globally in 2015. A national MDR-TB
survey, conducted in 2007 demonstrated that 5.7% of
new cases and 25.6% of previously treated cases had
MDR-TB, and approximately 8% of the patients with
MDR-TB had XDR-TB [6].
The increasing number of people with MDR-TB and
XDR-TB represents a threat to national TB control ef-
forts [3], because the treatment of MDR-TB and XDR-
TB takes longer than drug-susceptible TB, has toxic side
effects and treatment outcomes are often poor. Ongoing
transmission, failure to diagnose drug resistant TB at ini-
tial presentation, and high mortality and treatment drop-
out rates are also challenges [7, 8]. According to the
WHO’s 2016 Global TB Report, in 2015, a total of 9, 662
MDR-TB and 357 XDR-TB patients were diagnosed and
confirmed by laboratory investigations in China; of
these, a total of 5691(58.9%) MDR-TB and 122 (34.2%)
XDR-TB patients started second-line TB treatment [2].
The treatment success rates for people with MDR-TB
and XDR-TB in 2013 were 55% and 22%, respectively
[2]. These treatment success rates are below the WHO
target of a 75% treatment success rate by the end of
2015 [9].
Information about treatment outcomes in patients
with drug resistant-TB and factors associated with poor
treatment outcomes is limited in China. Therefore, the
aim of this study was to assess treatment outcomes and
to identify factors associated with poor treatment out-
comes and loss to follow-up in a cohort of HIV negative
and culture-confirmed MDR-TB and XDR-TB patients
in Hunan Province, China.
Methods
Study design and setting
A retrospective cohort study was conducted in Hunan
Province, China. The province is located in central-south
China and has a population of approximately 72 million
people [10]. The average annual TB incidence rate in
Hunan Province was 78.9 per 100,000 population during
the period 2005–2009 [11]. The proportions of MDR- and
XDR-TB among all TB patients were 10.6–25.2% and
1.8% [12, 13], higher than the national proportions [6].
Hunan Chest Hospital is the only chest hospital in the
province. It is located in Changsha, the capital city of
the province. The hospital has 610 beds, and provides
diagnostic and treatment services for patients with chest
and lung diseases including TB, MDR-TB, and XDR-TB,
who are referred from throughout the province. In 2011,
the hospital established an MDR-TB treatment centre
which provides comprehensive diagnostic and treatment
services for patients with drug resistant TB. The MDR
TB treatment centre serves as a referral hospital for all
persons with presumptive drug resistant TB in the prov-
ince, although those with known HIV co-infection go to
a different hospital.
MDR- TB and XDR-TB diagnosis
Of the 131 counties in Hunan Province, 32 counties are
able to provide comprehensive diagnostic services, which
include culture. However, drug susceptibility testing
(DST) is mainly carried out in the Hunan Chest Hos-
pital. Thus, sputum specimens from all culture-positive
TB patients from throughout the province are referred
to the Hunan Chest Hospital for DST. In the hospital,
phenotypic DST based on solid and liquid culture tech-
niques, and molecular methods using line probe assays
as well as Xpert® MTB/RIF are performed. At the Hunan
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Chest Hospital, DST is performed for rifampicin, isonia-
zid, ethambutol, streptomycin, kanamycin, and ofloxacin.
For the initial diagnosis of MDR-TB, liquid cultures are
used for 9 (1.9%) of cases and solid cultures are used for
472 (98.1%) of cases. Solid culture is also used for the
follow-up of patient’s progress and treatment outcomes.
Treatment regimen and management
Patients with bacteriologically confirmed MDR-TB and
XDR-TB are admitted to the MDR-TB treatment centre at
the Hunan Chest Hospital for treatment and management.
Patients are treated with an individualized treatment regi-
men containing four drugs, based on their DST results
and history of previous TB treatment. The regimen usually
includes an injectable agent (i.e. kanamycin, amikacin or
capreomycin), a fluoroquinolone (i.e. levofloxacin, ofloxa-
cin or moxifloxacin), para-aminosalicylic acid, prothiona-
mide, pyrazinamide, clarithromycin, ethambutol, or
cycloserine. The duration of treatment is 24 months for
patients with MDR-TB and 30 months for patients with
XDR-TB. The injectable drugs are used for a minimum of
6 months for MDR-TB patients, and 12 months for XDR-
TB patients. Patients are admitted to the hospital for one
to 2 months during the intensive phase and while hospita-
lised, receive directly observed therapy (DOT) by trained
medical staff. During this time, patients also receive psy-
chological support and counselling from hospital nurses.
When the patients are medically fit, they are treated as
out-patients. They receive support from trained family
members or from trained supervisors in the community
and return to the hospital once a month for a drug refill.
As part of routine care, sputum microscopy and cultures
are performed monthly for the first 2 months, and there-
after every other month until the end of treatment.
Data sources and variables
All MDR-TB and XDR-TB patients registered from the es-
tablishment of the MDR-TB treatment centre from 2011 to
2014 were included in this study. This period was purposely
selected so that 24-month treatment outcomes could be
assessed. Patients who were diagnosed with MDR-TB but
who did not start treatment were excluded from the study.
Patients who were transferred out and whose treatment
outcomes were not assessed were also excluded.
Patient information including socio-demographic char-
acteristics such age, sex, and occupation; clinical vari-
ables such as year treatment commenced, treatment
outcomes, duration of therapy and previous TB treat-
ment history; as well as smear, culture and DST results,
were obtained from an internet-based TB Management
Information System in the Tuberculosis Control Insti-
tute of Hunan Province, and from MDR-TB medical re-
cords and the DST registration book at Hunan Chest
Hospital. Given that all TB and HIV co-infected patients
are treated in a separate hospital, the cohort did not in-
clude information about HIV status and all patients in-
cluded in this study were assumed to be HIV-negative.
Information obtained from the different data sources
was linked using the patient’s registration number.
Treatment outcomes
Treatment outcomes are assigned by a team of physi-
cians working in the hospital based on the patient’s
progress (i.e. based on adherence to treatment and
signs of clinical improvement), and culture results. In
the surveillance system, treatment outcomes are re-
corded as cured, treatment completed, died, treatment
failure (failure due to side effects, or failure due to
other reasons), lost to follow-up (i.e. default) or not
evaluated (others). These treatment outcomes are based
on WHO recommendations [14]. Treatment outcomes
were defined as follows:
 Cured was defined as someone who completed
treatment without evidence of treatment failure and
who had three or more consecutive negative
cultures taken at least 30 days apart, after the
intensive phase.
 Treatment completed was defined as a patient who
had completed treatment but did not meet the
definition for cured due to a lack of bacteriological
results.
 Treatment failure was defined as treatment
terminated or a need for permanent regimen change
of at least two anti-TB drugs due to an adverse drug
reaction, or lack of culture conversion by the end of
the intensive phase, or bacteriological reversion in
the continuation phase after conversion to negative
after intensive phase, or evidence of additional ac-
quired resistance to fluoroquinolones or second-line
injectable drugs.
 Lost to follow-up was defined as a patient whose
treatment was interrupted for two consecutive
months or more.
 Death was defined as those who died for any reason
during the course of treatment.
Treatment outcome, the dependent variable of this
study, was categorized into two mutually exclusive
groups: 1) treatment success if the patient was cured or
completed treatment; and 2) unfavourable outcomes if
the patient died, had an outcome of treatment failure, or
was lost to follow-up. For further analysis, unfavourable
treatment outcomes were separated into two groups: 1)
lost to follow-up if the patients were “lost” during treat-
ment; and 2) poor treatment outcome if the patient died
or had an outcome of treatment failure.
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Data analysis
We undertook descriptive analyses, calculating means
with standard deviations (SD) for normally distributed
continuous variables, medians with an interquartile
range (IQR) for non-normally distributed continuous
variables and percentages for categorical variables. In
addition, we used Fisher’s exact test for comparison of
categorical variables and the Wilcoxon rank sum test for
the comparison of ordinal or continuous measures.
Cumulative incidence functions were used to estimate
time to events (i.e. time to poor treatment outcomes,
time to loss to follow-up, and time to unfavourable out-
comes); and a competing-risks survival regression model
was used to identify predictors of treatment outcomes.
The analysis included all drug-resistant cases (i.e. both
MDR-TB and XDR-TB cases).
Time to treatment outcomes was measured in
months from the start of MDR/XDR-TB treatment to
the occurrence of the outcome event. In the analysis,
successful treatment outcomes (i.e. cured or treatment
completed) were considered as censored. Three differ-
ent events were considered separately to analyze the
different type of treatment outcomes individually and
to see their composite outcomes. The first event was
time to unfavourable treatment outcomes (i.e. poor
treatment outcome, or loss to follow up, whichever
came first) and it was a composite of the second and
the third events. The second event was time to loss
to follow up, and the third event was time to poor
treatment outcome (i.e. death or treatment failure,
whichever came first). In the time to poor treatment
outcome analysis, loss to follow-up was considered as
a competing risk (i.e. events that occur instead of the
event of interest). This computing event (i.e. loss to
follow up) cannot be treated as censored because it
might be dependent on poor treatment outcome that
could not be measured using the current data. Simi-
larly, in the time to loss to follow-up analysis, death
was considered as a competing risk. In the presence
of competing events, it is recommended to use cause-
specific hazards rather than standard hazards, and cu-
mulative incidence estimates rather than the Kaplan-
Meier survival estimates [15]. Therefore, we used
competing-risks survival regression models, instead of
Cox regression models, to identify the predictors of
poor treatment outcomes and loss to follow-up. Vari-
ables with statistical significance at p < 0.2 in the bi-
variate analysis, and variables with clinical significance
(i.e. irrespective of their statistical significance) based
on the literature, were fitted in the final multivariate
analysis. Crude and adjusted hazard ratios with their
95% CI intervals were calculated to measure time to
treatment outcomes. The analysis were performed
using STATA version 14.1 [16].
Results
Demographic characteristics
A total of 493 patients were registered with a diagnosis
of MDR-TB or XDR-TB during 2011–2014. Four pa-
tients had not commenced treatment after a diagnosis of
MDR-TB and eight patients whose treatment outcome
was not recorded were excluded from the study. Thus,
the remaining 481 patients (471 MDR-TB and 10 XDR-
TB) were eligible and were included in the analysis. The
majority of patients were farmers (380; 79%) and male
(340; 71%). The mean age of the patients was 40 years
(SD ±13 years). Table 1 summarizes the demographic
and clinical characteristics of patients.
Clinical characteristics
The prevalence of XDR-TB among all culture-
confirmed MDR-TB was 2% (95% CI: 1% -4%). The
majority of MDR-TB (408; 87%) and XDR-TB (9;
90%) patients had been previously treated for TB or
MDR-TB. Of the 417 previously treated patients, 8
(2%) patients were previously treated with both first-
line and second-line anti-TB drugs, and 409 (98%) pa-
tients were treated with first-line anti-TB drugs only.
The median time for culture conversion was higher
in XDR-TB patients at 5 months (IQR 1–20 months)
than in MDR-TB patients at 1 month (IQR: 1–
2 months) (p = 0.03). The duration of hospitalization
was recorded for 321 patients. The median length of
hospital stay for these patients was 23 days (IQR = 18–
31 days); 23 days (IQR = 18–31 days) for MDR-TB
patients and 22 days (IQR = 20–29 days) for XDR-TB
patients. The median hospital stay was similar for pa-
tients with a successful treatment outcome (21 days;
IQR 17–31 days), a poor treatment outcome (23 days;
IQR18–30 days) and loss to follow-up (24.5 days; IQR
18–32 days).
Treatment outcomes
Of all 481 MDR-TB and XDR-TB patients, 262 (54%)
were cured, 14 (3%) completed treatment, 13 (3%) died,
63 (13%) had treatment failure and 130 (27%) were lost
to follow-up. Of 10 patients with XDR-TB, 3 (30%)
were cured, 3 (30%) had treatment failure, and 4 (40%)
were lost to follow-up. The overall treatment success
rate for all patients was 57% (95% CI: 52%–61%), 58%
for patients with MDR-TB (n = 272) and 30% for pa-
tients with XDR-TB (n = 3) (Table 1). Overall, 76 (21%)
patients had poor treatment outcomes (13 patients died
and 63 patients had treatment failure). The proportion
of poor treatment outcomes did not differ when com-
paring those with or without previous anti-TB treat-
ment; 70 (17%) versus 6 (9%) among patients without
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and with a history of previous TB treatment, respect-
ively (p = 0.2; Table 2).
Survival analysis of all MDR/XDR-TB patients
More than two thirds (77%) of poor treatment outcomes
occurred during the continuation phase (i.e. after 6 months
of therapy). For all patients, the cumulative probability of
a poor treatment outcome at the end of 6 months was 5%,
at the end of 1 year was 7%, and at the end of 2 years was
18% (Fig. 1). Patients with an outcome of lost to follow-up
interrupted treatment after a median of 10 months of
treatment (IQR: 5–14 months); two thirds (87/130 or
Table 1 Demographic and clinical characteristics of patients with multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis
in Hunan Province, China, from 2011 to 2014
Characteristics Total
n = 481
MDR-TBa
n = 471
XDR-TBb
n = 10
P-value*
Age in years, mean ± SDa 40.4 ± 12.9 40.4 ± 12.9 40.6 ± 11.3 0.85
Male gender, n (%) 340 (70.7) 331 (70.3) 9 (90.0) 0.29
Occupation, n (%) 0.11
Farmer 380 (79.0) 374 (79.4) 6 (60.0)
Labourer 15 (3.1) −
Employed 16 (3.3) 15 (3.2) −
Unemployed 19 (3.8) 16 (3.4) −
Other/unknown 51 (10.6) 19 (4.0)
47 (10.0)
4 (40.0)
Year treatment commenced, n (%) 0.10
2011 2 (0.4) 2 (0.4) −
2012 118 (24.5) 116 (24.2) 4 (40.0)
2013 164 (34.1) 159 (33.7) 5 (50.0)
2014 197 (40.9) 196 (41.6) 1 (10.0)
Positive sputum smear result at commencement, n (%) 477 (99.1) 467 (99.1) 10 (100.0) 0.91
Previous TB or MDR-TB treatment, n (%) 417 (86.7) 408 (86.6) 9 (90.0) 0.60
Resistant number of drugs, median (IQR) 3 (2–4) 3 (2–4) 5 (5–6) 0.05
Resistant to Ethambutol (E), n (%) 165 (34.3) 161 (34.2) 4 (40.0) 0.80
Resistant to Streptomycin (S), n (%) 288 (59.9) 279 (59.2) 9 (90.0) 0.19
Resistant to Ofloxacin (Ofx), n (%) 46 (9.6) 37 (7.9) 9 (90.0) <0.001
Resistant to Kanamycin (Km), n (%) 15 (3.1) 6 (1.3) 9 (90.0) <0.001
Treatment outcome, n (%) 0.14
Cured 261 (54.3) 258 (54.8) 3 (30.0)
Completed 14 (2.9) 14 (2.9) −
Successful treatment (cured + completed) 275 (57.2) 272 (57.8) 3 (30.0)
Died 13 (2.7) 13 (2.8) −
Failure 63 (13.1) 60 (12.7) 3 (30.0)
Poor treatment outcome (death + failure) 76 (15.8) 73 (15.5) 3 (30.0)
Lost to follow up 130 (27.0) 126 (26.8) 4 (40.0)
Unfavourable outcome (died + failure +lost to follow-up) 206 (42.8%) 199 (42.3) 7 (70)
Duration of therapy in months, median (IQRc) 24 (13–25) 24 (13–25) 22.5 (14–26) 0.87
Sputum smear conversion, n (%) 414 (86.1) 404 (85.8) 10 (100) 0.37
Culture conversion, n (%) 386 (80.2) 380 (80.7) 6 (60.0) 0.11
Time of sputum smear conversion in months, median (IQRc) 1(1–2) 1(1–2) 1.5 (1–8) 0.37
Time of culture conversation in months, median (IQRc) 1 (1–3) 1 (1–2) 5 (1–20) 0.03
aMDR-TB multidrug resistant tuberculosis, SD standard deviation, bXDR-TB, extensively drug-resistant tuberculosis
cIQR inter quartile range
*Comparison between MDR-TB and XDR-TB patients calculated with Wilcoxon rank-sum test for continuous variables and Fisher’s exact test for categorical variables
Alene et al. BMC Infectious Diseases  (2017) 17:573 Page 5 of 11
67%) occurred during the continuation phase of treat-
ment. The cumulative probability of loss to follow-up at
the end of 6 months was 9%, at the end of 1 year was 21%,
and at the end of 2 years was 31% (Fig. 2). The overall cu-
mulative probability of unfavorable outcomes (i.e. death,
treatment failure or loss to follow up combined) was 12%
at the end of 6 months, 23% at the end of 1 year, and 40%
at end of 2 years (Fig. 3). The median hazard time or the
time at which the cumulative hazard function of an un-
favourable outcome in all patients was equal to 0.5, was
27 months (Fig. 3).
Patients who started treatment in 2011–2012 and
2013 had shorter survival times than patients who
started treatment in 2014. The cumulative probabilities
of a poor treatment outcome at the end of 1 year and 2
years were 13% and 27% for patients who started treat-
ment in 2011–2012, 7% and 20% for patients who
started treatment in 2013, and 3% and 11% for patients
who started treatment in 2014, respectively (Fig. 4).
Predictors of poor treatment outcome and lost to
follow-up
Resistance to ofloxacin was an independent predictor of
poor (AHR = 3.1; 95%CI = 1.5, 6.3), and unfavourable
(AHR = 1.7; 95%CI = 1.07, 2.9) treatment outcomes. Pa-
tients who started treatment during 2013 had an almost
two times higher risk of poor treatment outcomes com-
pared to patients who started treatment during 2014
(AHR = 2.1; 95% CI = 1.2, 3.9). Moreover, patients who
started treatment during 2011–2012 had an almost three
times higher risk of poor treatment outcomes compared
to patients who started treatment during 2014
(AHR = 2.8; 95% CI = 1.5, 5.3). When we compared
those who were lost to follow-up to those with a suc-
cessful treatment outcome, no statistically significant
hazard ratio was observed (Table 3).
Discussion
This is the first published study that has summarised
treatment outcomes from a cohort of HIV negative and
culture-confirmed MDR-TB and XDR-TB patients in
Hunan Province, China. The overall rate of treatment
success was 57% (95% CI: 52%–61%). This result is con-
sistent with reported global (52%) and national (56%)
MDR-TB treatment success rates [2, 6], and with the
MDR-TB treatment success rate recorded in another
study conducted in patients from Chinese referral hospi-
tals [17]. However, the rate is still far short of the WHO
target of 75% treatment success, and lower than in other
studies conducted in Pakistan [18], Switzerland [19], the
United Kingdom [20], Ethiopia [21], and Portugal [22].
Low treatment success rates have been also reported in
Table 2 Treatment outcomes of multidrug-resistant tuberculosis
and extensively drug-resistant tuberculosis patients stratified by
previous anti-TB treatment in Hunan Province, China, from 2011
to 2014
Treatment outcome No. (%) patients
previously treated,
n = 417
No. (%) patients
not previously
treated, n = 64
P-value
Cured 228 (54.7) 33 (51.6) 0.20
Completed 11 (2.6) 3 (4.7)
Successful treatment
(cured + completed)
239 (57.3) 36 (56.3)
Died 11 (2.6) 2 (3.1)
Failure 59 (14.2) 4 (6.2)
Poor treatment outcome
(death + failure)
70 (16.8) 6 (9.4)
Lost to follow up 108 (25.9) 22 (34.4)
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Fig. 1 Cumulative hazard estimate of the probability of a poor treatment outcome (i.e. death or failure) in patients with multidrug-resistant tuberculosis
and extensively drug-resistant tuberculosis in Hunan Province, China, 2011–2014
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other studies conducted in China among similar patient
groups (i.e. among those who are HIV-negative with
culture-confirmed MDR-TB or XDR-TB) [23, 24]. This
low rate of treatment success among MDR-TB patients
poses a serious threat for national TB control efforts as
patients may develop additional resistance and may also
transmit drug resistant forms of TB to others [25, 26].
In our study, the prevalence of XDR-TB among all
MDR-TB was 2% (95% CI: 1%-4%). This is a similar find-
ing to a study conducted in Beijing that reported a
prevalence of XDR-TB among all MDR-TB patients of
1.4% [17]. However, it is lower than the results from the
national drug resistance survey, and other population-
based and hospital-based studies from China, which
have reported a prevalence of XDR-TB ranging from 8%
to 12% among all MDR-TB patients [6, 23, 27, 28]. This
may be due to the fact that our study subjects were
HIV-uninfected. In a previous study, it was reported that
HIV infection is a risk factor for XDR-TB [29]. The
lower prevalence could be also due to differences in the
setting and time period. Geographical variation has been
reported in the occurrence of drug resistance TB in
China [30]. The proportions of MDR- and XDR-TB
among TB patients were higher in some provinces than
the overall national prevalence [6, 12, 13].
The other important finding of our study was that just
over one quarter (27%) of the patients were lost to
follow-up. This was higher compared to a pooled rate of
13% identified in a systematic review, and with results
from other studies conducted in South Africa (17%
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Fig. 2 Cumulative hazard estimate of the probability of loss to follow-up in patients with multidrug-resistant tuberculosis and extensively drug-
resistant tuberculosis in Hunan province, China, 2011–2014
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Fig. 3 Cumulative hazard estimate of the probability of an unfavorable treatment outcome (i.e. death, treatment failure or loss to follow-up) in patients
with multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis in Hunan Province, China, 2011–2014
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-20%), Malaysia (17%) and the United Kingdom (7.8%)
[20]. It was also higher than results reported from
Beijing (17.4%) [17], and other parts of China (5.46%)
[23]. Loss to follow up mainly occurred during the con-
tinuation phase of treatment (i.e. after 6 months of treat-
ment), unlike a study conducted in Ethiopia in which
loss to follow-up occurred during the intensive phase of
treatment [21]. The proportion of patients lost to
follow-up contributes to the low treatment success rate.
To solve this problem in Hunan Province, the hospital
has designed a tracing mechanism whereby patients who
are not yet enrolled on treatment and who miss the
monthly follow-up appointment are notified to the
Center for Disease Control and prevention (CDC) staff
of the county where the patient resides. Then the CDC
staff, with the assistance of the local health professionals,
trace the patient and discuss with them the importance
of continuing their treatment. A study of the reasons for
loss to follow-up conducted in the Hunan Chest Hos-
pital using this tracing mechanism, found that patients
were lost due to: economic hardship; a misconception
that they were cured when their symptoms resolved or
Hazard ratio (HR:2.8; 95%CI:1.5-5.3)
Hazard ratio (HR:2.1; 95%CI:1.2-3.9)
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Fig. 4 Cumulative hazard estimate of the probability of poor treatment outcome (i.e. death or treatment failure) in patients with multidrug-
resistant tuberculosis and extensively drug-resistant tuberculosis by year of initiation of treatment in Hunan Province, China, 2011–2014
Table 3 Predictors of poor treatment outcome (i.e. death or failure), loss to follow-up, and unfavourable outcomes (i.e. death, treatment
failure, or loss to follow-up) in patients with multidrug-resistant and extensively drug-resistant tuberculosis in Hunan Province, China,
2011–2014
Variables Poor treatment outcome Lost to follow up Unfavourable outcome
CHRb
(95% CI)
AHRc
(95% CI)
CHRb
(95% CI)
AHRc
(95% CI)
CHRb
(95% CI)
AHRc
(95% CI)
Age in years 1.0 (0.9–1.0) 1.0 (0.9–1.01) 1.01(1.0–1.03) 1.0 (0.9–1.02) 1.01 (1.0–1.02) 1.01 (1.0–1.02
Male gender 1.2 (0.7–2.0) 1.1 (0.7–1.8) 1.4 (0.9–2.2) 1.4 (0.9–2.1) 1.4 (1.04–2.0) 1.3 (0.97–1.9)
Occupationa
Labourer 0.5 (0.1–3.1) 0.3 (0.06–2.1) 1.6 (0 .7–3.8) 1.9 (0.8–4.3) 1.2 (0.6–2.7) 1.3 (0.6–2.8)
Employed 0.4 (0.1–3.0) 0.4 (0.05–3.2) 0.6 (0.2–2.0) 0.7 (0.2–2.4) 0.5 (0.2–1.4) 0.6 (0.2–1.5)
Unemployed 2.0 (0.7–4.9) 1.8 (0.7–4.8) 1.1 (0.5–2.) 1.4 (0.6–3.2) 1.5 (0.8–2.7) 1.7 (0.9–3.2)
Other/unknown 1.5 (0.8–2.8) 1.4 (0.7–2.6) 0.9 (0.5–1.6) 1.01 (0.5–1.8) 1.0 (0 .7–1.6) 1.1 (0.7–1.8)
Treatment starting yeara
2011–2012 2.8 (1.5–5.2) 2.8 (1.4–5.0) 0 .6 (0.4–1.1) 0.6 (0.3–1.03) 1.1 (0 .7–1.5) 1.0 (0.7–1.5)
2013 2.1 (1.2–3.8) 2.0 (1.1–3.8) 0 .7 (0 .5–1.1) 0.7 (0.5–1.1) 1.0 (0.7–1.4) 0.9 (0.7–1.4)
Previous anti-TB treatment 1.8 (0.8–4.2) 1.8 (0.8–4.2) 0 .7 (0.5–1.2) 0.8 (0.5–1.2) 0.9 (0.6–1.4) 0.9 (0.6–1.4)
Resistant to Ethambutol 1.2 (0.8–2.0) 1.3 (0.8–2.1) 1.1 (0.7–1.5) 1.1 (0.7–1.6) 1.1 (0.8–1.5) 1.2 (0.9–1.6)
Resistant to second-line injectable drug 1.3 (0.8–2.2) 1.3 (0.8–2.1) 0.7 (0 .4–1.0) 0.7 (0.5–1.02) 0 .8 (0.6–1.1) 1.7 (0.5–5.4)
Resistant to Ofloxacin 2.8 (1.4–5.6) 3.1 (1.5–6.3) 0.9 (0.4–1.8) 1.01 (0.5–2.1) 1.5 (0.9–2.5) 1.7 (1.07–2.9)
aFor occupation farmer, and for treatment starting year 2014 was the referent category
bCHR, crude hazard ratio; cAHR, adjusted hazard ratio
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when they were informed of their culture conversion re-
sult from positive to negative; death – that was not re-
ported to the TB programme or the hospital; and
emigration to another area for work [31]. Adopting and
implementing the shorter MDR-TB regimen (i.e. with a
treatment duration of 9–12 months), recently recom-
mended by WHO, might be a solution for reducing the
proportion of patients lost to follow up, especially for pa-
tients who interrupt their treatment as a result of
outwards-migration and economic hardship [32].
Additionally, a high rate of treatment failure was ob-
served in our study. Almost all MDR-TB patients who had
the outcome of treatment failure were sputum smear posi-
tive at the start of treatment. Presumably, these patients
remained sputum smear positive throughout treatment.
This ongoing infectiousness might contribute to a serious
epidemic of drug-resistant TB in China [6], including
primary transmission of MDR-TB and XDR-TB [33].
Recent studies have shown that high number of cases
with MDR-TB and XDR-TB occurred due to primary
transmission [7, 8, 34].
The number of patients diagnosed with MDR-TB and
started on treatment has increased over time. Treatment
outcomes have also improved over time. The proportion
of patients who experienced poor treatment outcomes
was higher in patients who started treatment during
2011 and 2012 than patients who started treatment dur-
ing 2014. This might indicate improvements in care over
time, including improved diagnostic services, treatment
and follow up. Since 2013, the hospital has introduced
new molecular diagnostic methods such as line probe as-
says and Xpert® MTB/RIF, that shorten the diagnostic
period. Additionally, with the support of funds from the
Global Fund to fight AIDS, TB and Malaria, new anti-TB
agents such as capreomycin and cycloserine were used for
the treatment of MDR-TB for the first time in 2013.
Meanwhile, a tracing mechanism was implemented to
support follow up of patients during this period.
We also found that resistance to ofloxacin was an in-
dependent predictor of poor treatment outcomes, which
concurs with previous studies showing that baseline
ofloxacin resistance was associated with poor MDR-TB
treatment outcomes [35–38]. This finding suggests the
importance of fluoroquinolones, especially ofloxacin in
MDR-TB treatment. Baseline DST for fluoroquinolones
will ensure appropriate administration of an effective
regimen for MDR-TB patients.
This study has some limitations. Firstly, since the
study was based on secondary data, some important var-
iables such as types of anti-TB drug prescribed to the
patients; side effects of the drugs; haematological data
such as hemoglobin and liver function test results; and
co-morbidities were not available in the registers and
therefore were not included in our study. Secondly, the
small number of patients with XDR-TB may have limited
our ability to comprehensively assess treatment out-
comes and predictors of poor treatment outcomes.
Thirdly, since all HIV and TB co-infected patients in
China are referred to HIV-specialized hospitals and not
admitted to Chest Hospitals, our study has not assessed
the impact of HIV infection on the treatment outcomes
of MDR-TB and XDR-TB patients. Previous studies have
shown that in countries where patients with XDR-TB
also had HIV co-infection, extremely high mortality rates
have been reported [23, 39–43].
Conclusions
The present study showed sub-optimal treatment suc-
cess rates among patients with MDR-TB and XDR-TB,
and high rates of loss to follow-up in Hunan Province,
China. However, the study has provided some evidence
that treatment success rates have increased over time.
Resistance to ofloxacin was an independent predictor of
poor treatment outcomes. Strategies should be designed
to reduce the high rate of poor treatment outcomes and
loss to follow-up.
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